Deciding when to operate on a patient with chronic aortic regurgitation may be extremely difficult. The timing of surgery requires consideration of the etiology and pathophysiology of the aortic regurgitation, because aortic valve replacement carries morbidity and mortality that must be weighed against the potential problems of continued medical management. Guidelines for the use of surgery in patients with valvular disease have been developed by a joint task force of the American College of Cardiology and the American Heart Association. Practical recommendations based on these guidelines are presented. (Am Fam Physician 2001;64:1709-14.)
Determining the point at which surgery is needed is more difficult in patients with chronic aortic regurgitation than in patients with other valvular lesions. If the aortic regurgitation develops gradually, the left ventricle can become enormous, but the patient may have few or no symptoms. Even in the absence of symptoms, the etiology of aortic regurgitation needs to be considered in deciding if and when to operate. This article discusses the pathophysiologic basis of the signs and symptoms of aortic regurgitation, with the purpose of providing practical recommendations to help physicians determine when surgical intervention is necessary.
Aortic regurgitation can have many causes, including diseases that affect connective tissue, which is the substance of the aortic valve and the ascending aorta (Table 1). In most of these diseases, aortic regurgitation progresses gradually, allowing time for the left ventricle to accommodate the large diastolic volume by increasing its end-diastolic size and developing eccentric hypertrophy. A few diseases can cause sudden severe aortic regurgitation. In these diseases, the clinical picture of acute aortic regurgitation results from a sudden and marked increase in diastolic filling volume, with no chance for the left ventricle or the stiff pericardium to accommodate this increase.
In chronic aortic regurgitation, valvular surgery is needed when the regurgitant volume becomes moderate to severe. However, certain etiologies may dictate surgery even if the degree of regurgitation is mild. For instance, the patient with aortic regurgitation resulting from dissection of the ascending aorta requires immediate surgery to repair the dissection. The patient with a prosthetic aortic valve who presents with infective endocarditis and an extensive annular abscess should undergo surgery before massive dehiscence occurs. Finally, the patient with a large ascending aortic aneurysm and minimal aortic regurgitation must have surgery because of the aneurysm.
Pathophysiology of Chronic Aortic Regurgitation
The diagnosis of aortic regurgitation can be made using a stethoscope. Its severity is reflected by the peripheral signs of aortic regurgitation.
In chronic aortic regurgitation, the regurgitant leak increases gradually so that the end-diastolic left ventricular volume becomes greater. The left ventricle responds with dilatation and hypertrophy (eccentric hypertrophy). With a large left ventricle, stroke volume increases enough to keep the forward effective stroke volume normal and accommodate the regurgitant volume. As the aortic regurgitation becomes severe, the increased left ventricular stroke volume delivered into the aorta results in a high systolic pressure, and the rapid runoff from the aorta back into the left ventricle results in a lower aortic diastolic pressure. Ultimately, the difference between systolic and diastolic pressure (pulse pressure) increases. The aorta becomes dilated and elongated, which explains the uncoiled aorta usually seen on the chest radiograph.
The increased pulse pressure and rapid aortic runoff result in many of the peripheral signs of severe aortic regurgitation, including the visible carotid pulse and suprasternal pulsations as well as the collapsing quality of the pulse ("water-hammer" pulse, Quincke's pulse [pulsating flushing of the nail beds]). In severe aortic regurgitation, the retrograde flow back into the left ventricle results in the to-and-fro bruit created by pressure with the bell of the stethoscope placed over the femoral artery (Duroziez's murmur). The rapid ejection of the large stroke volume leads to a sharp rise in the pulse wave, resulting in the "pistol-shot" femoral artery sound.
Pathophysiologically, the left ventricle must continue to eject a large stroke volume to keep forward stroke volume normal. The higher systolic pressure, together with the larger end-diastolic volume, results in both an afterload and a preload burden on the left ventricle. When the left ventricle can no longer deliver this stroke volume against the increased afterload, the amount of blood remaining in the ventricle increases (end-systolic volume), and the end-diastolic volume also increases to maintain the left ventricular stroke volume. This results in a decrease in the percentage of end-diastolic volume ejected, or a decreased ejection fraction. As the left ventricle enlarges and myocardial dysfunction occurs, the filling pressure rises, and the patient develops signs and symptoms of left ventricular failure.
Another problem is the effect of chronic severe aortic regurgitation on the myocardial oxygen supply/demand ratio. The demand for myocardial oxygen, and therefore coronary blood flow, is increased because the left ventricle is large and left ventricular systolic pressure has increased. At the same time, myocardial blood flow is decreased, especially to the subendocardial regions, because of the low diastolic aortic pressure. The imbalance of myocardial oxygen supply and demand may result in myocardial ischemia and its complications: angina, myocardial infarction and fibrosis, ventricular arrhythmias, syncope and sudden death.
The diagnosis of aortic regurgitation is made with the stethoscope and is based on the finding of a "decrescendo" blowing diastolic murmur, which is best heard along the left sternal border.
Doppler echocardiography would show a regurgitant aortic jet in a small percentage of the general population. The leak is so small in volume that a murmur is not heard. It is presumed that this degree of aortic regurgitation is normal and does not represent disease. If no murmur or peripheral signs of aortic regurgitation are present, a diagnosis of aortic regurgitation should not be made, and no follow-up echocardiography is needed.
If the aortic regurgitation is mild, the murmur may be quite high-pitched and may fade out during diastole. If the aortic regurgitation is moderate to severe and chronic, the murmur, although still blowing, is of lower frequency and louder, and usually lasts throughout diastole. Because of the large left ventricular stroke volume, a systolic ejection murmur may also be heard. This murmur can be loud and long enough to sound like aortic stenosis.
When both diastolic and systolic murmurs are heard, the decision as to which lesion (aortic stenosis or regurgitation) is significant is based on the presence of peripheral signs. If the patient has peripheral signs of aortic regurgitation, no matter how loud the systolic murmur or how soft the diastolic murmur, significant aortic regurgitation should be presumed.
The presence and severity of aortic regurgitation can usually be determined based on the physical examination alone. However, Doppler echocardiography should be performed to confirm the presence of the regurgitation, quantify its severity and look for other cardiac problems (e.g., valvular vegetations, ventricular septal defect or aortic root aneurysm) that may be important in guiding therapy.
Consideration of Aortic Valve Replacement
The presence of aortic regurgitation, even when it is moderately severe, is not necessarily an indication for surgery. When surgery is needed, aortic valve replacement, rather than repair, is usually required. Prosthetic valves, whether mechanical or biologic, have problems with durability, paraprosthetic leaks, thromboembolism and increased susceptibility to infective endocarditis. The decision to replace the valve requires that these potential problems be considered to represent less danger to the patient's well-being than continuing medical management.
NATURAL HISTORY OF AORTIC REGURGITATION
The natural history of chronic aortic regurgitation is well recognized. The asymptomatic patient who has moderate to severe aortic regurgitation may not have symptoms for many years. In seven studies,(1-7) 490 asymptomatic patients with moderate to severe aortic regurgitation were followed for a mean of 6.4 years. Based on these studies, the following can be concluded about asymptomatic chronic aortic regurgitation with normal left ventricular systolic function (i.e., an ejection fraction of 50 percent or greater)8:
1. The rate of progression to symptoms and/or left ventricular dysfunction is less than 6 percent per year.
2. The rate of progression to asymptomatic left ventricular dysfunction is less than 3.5 percent per year.
3. The rate of sudden death is less than 0.2 percent per year.
In patients with asymptomatic chronic aortic regurgitation and left ventricular dysfunction, the rate of progression to symptoms is higher than 25 percent per year. In symptomatic patients, the mortality rate is greater than 10 percent per year.(8)
Although there is only a small chance of sudden death or left ventricular dysfunction in patients with asymptomatic chronic aortic regurgitation, these adverse events are possible. Therefore, it is important to follow asymptomatic patients for the development of symptoms and to examine them regularly to detect progression of severity. In addition, periodic quantitative evaluation of left ventricular function is necessary in patients with moderate to severe aortic regurgitation. When the history of exercise tolerance or symptoms is equivocal, exercise stress testing can be helpful.
MEDICAL TREATMENT OF AORTIC REGURGITATION
The use of afterload-reducing agents such as nifedipine (Procardia), an angiotensin-converting enzyme inhibitor or hydralazine (Apresoline) in asymptomatic patients with moderate to severe aortic regurgitation has been shown to decrease the progression of cardiac enlargement and even postpone the timing of valve replacement.(6,9,10) Afterload-reducing agents, however, are not indicated when aortic valve replacement is really needed.
PREOPERATIVE RISK ASSESSMENT
Many investigators have studied factors that predict survival and recovery of left ventricular function after aortic valve replacement. In several studies,(11,12) the development of New York Heart Association (NYHA) class III and IV symptoms, especially with an ejection fraction of less than 50 percent, was most predictive of increased mortality and decreased left ventricular myocardial function after aortic valve replacement. The duration of symptoms can also be important: the longer the patient has symptoms and the longer left ventricular dysfunction has been present before surgery, the worse the outcome.(11,13)
Doppler two-dimensional echocardiography is most often used to evaluate left ventricular function, but radioisotope angiography has also been employed to measure left ventricular volume and the ejection fraction. The measurements usually made by M-mode echocardiography are end-diastolic diameter, end-systolic diameter and fractional shortening. With two-dimensional echocardiography and radioisotope angiography, ejection fraction is most helpful in following the status of left ventricular function. Cutoff points have been 55 mm for end-systolic diameter, 25 percent for fractional shortening and 50 percent for ejection fraction.(1,3,11,14,15)
In asymptomatic patients with moderate to severe aortic regurgitation and normal systolic function, periodic quantitative evaluation of left ventricular function in the absence of a change in clinical status is recommended to look for the development of left ventricular dysfunction. No evidence supports a specific time between evaluations, but the current recommendation is every six months.(8)
Because of its effects on left ventricular end-systolic volume, end-diastolic volume and ejection fraction, exercise stress testing has been advocated for use in finding incipient decreases in myocardial function.(7,16) Normally, the ejection fraction increases with exercise. In patients who are at the end of cardiac reserve, the end-systolic ventricular volume increases and the ejection fraction decreases with exercise. It is not clear that an exercise ejection fraction is a better method than following the resting ejection fraction, exercise tolerance and symptoms in making a decision about proceeding to surgery.
Cardiac catheterization should be performed when noninvasive tests are inconclusive regarding the severity of aortic regurgitation or the status of left ventricular function, or when the findings of these tests are at odds with the clinical findings. Cardiac catheterization and coronary arteriography are also performed when it is necessary to evaluate patients at risk for coronary artery disease prior to surgery.
The American College of Cardiology and American Heart Association (ACC/AHA) Task Force on Practice Guidelines of the Committee on Management of Patients with Valvular Heart Disease reviewed the literature extensively.8 The report of this task force is a valuable resource for physicians to use in evaluating and managing patients with valvular disease. Current recommendations for aortic valve replacement are listed in Tables 2(8,17) and 3.(8) The New York Heart Association (NYHA) classification of functional capacity is given in Table 4.(18)
Surgery is not indicated in an asymptomatic patient with normal left ventricular systolic function at rest and mild left ventricular dilatation (end-diastolic diameter of less than 70 mm; end-systolic diameter of less than 50 mm). The medical management of patients with chronic aortic regurgitation is summarized in Table 5.
When aortic valve surgery with low or no operative mortality and no late complications becomes possible, valve replacement may be recommended as soon as the heart starts dilating and developing hypertrophy. However, surgery still has perioperative mortality and late morbidity. The use of surgery in an asymptomatic patient with chronic aortic regurgitation must be justified by good evidence of long-term benefit.
The authors indicate that they do not have any conflicts of interest. Sources of funding: none reported.
(1.) Bonow RO, Lakatos E, Maron BJ, Epstein SE. Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function. Circulation 1991;84:1625-35.
(2.) Scognamiglio R, Fasoli G, Dalla Volta S. Progression of myocardial dysfunction in asymptomatic patients with severe aortic insufficiency. Clin Cardiol 1986;9:151-6.
(3.) Siemienczuk D, Greenberg B, Morris C, Massie B, Wilson RA, Topic N, et al. Chronic aortic insufficiency: factors associated with progression to aortic valve replacement. Ann Intern Med 1989;110: 587-92.
(4.) Tornos MP, Olona M, Permanyer-Miralda G, Herrejon MP, Camprecios M, Evangelista A, et al. Clinical outcome of severe asymptomatic chronic aortic regurgitation: a long-term prospective follow-up study. Am Heart J 1995;130:333-9.
(5.) Ishii K, Hirota Y, Suwa M, Kita Y, Onaka H, Kawamura K. Natural history and left ventricular response in chronic aortic regurgitation. Am J Cardiol 1996;78:357-61.
(6.) Scognamiglio R, Rahimtoola SH, Fasoli G, Nistri S, Dalla Volta S. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med 1994; 331:689-94.
(7.) Borer JS, Hochreiter C, Herrold EM, Supino P, Aschermann M, Wencker D, et al. Prediction of indications for valve replacement among asymptomatic or minimally symptomatic patients with chronic aortic regurgitation and normal left ventricular performance. Circulation 1998;97:525-34.
(8.) Bonow RO, Carabello B, de Leon AC Jr, Edmunds LH Jr, Fedderly BJ, Freed MD, et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 1998;88:1949-84.
(9.) Greenberg B, Massie B, Bristow JD, Cheitlin M, Siemienczuk D, Topic N, et al. Long-term vasodilator therapy of chronic aortic insufficiency. A randomized double-blinded, placebo-controlled clinical trial. Circulation 1988;78:92-103.
(10.) Levine HJ, Gaasch WH. Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. J Am Coll Cardiol 1996; 28:1083-91.
(11.) Michel PL, Iung B, Abou Jaoude S, Cormier B, Porte JM, Vahanian A, et al. The effect of left ventricular systolic function on long term survival in mitral and aortic regurgitation. J Heart Valve Dis 1995; 4(suppl 2):S160-8.
(12.) Klodas E, Enriquez-Sarano M, Tajik AJ, Mullany CJ, Bailey KR, Seward JB. Optimizing timing of surgical correction in patients with severe aortic regurgitation: role of symptoms. J Am Coll Cardiol 1997;30: 746-52.
(13.) Bonow RO, Dodd JT, Maron BJ, O'Gara PT, White GG, McIntosh CL, et al. Long-term serial changes in left ventricular function and reversal of ventricular dilatation after valve replacement for chronic aortic regurgitation. Circulation 1988;78(5 pt 1):1108-20.
(14.) Henry WL, Bonow RO, Borer JS, Ware JH, Kent KM, Redwood DR, et al. Observations on the optimum time for operative intervention for aortic regurgitation. I. Evaluation of the results of aortic valve replacement in symptomatic patients. Circulation 1980;61: 471-83.
(15.) Chen L, Otto CM. Longitudinal assessment of valvular heart disease by echocardiography. Curr Opin Cardiol 1998;13:397-403.
(16.) Tarasoutchi F, Grinberg M, Filho JP, Izaki M, Cardoso LF, Pomerantezeff P, et al. Symptoms, left ventricular function, and timing of valve replacement surgery in patients with aortic regurgitation. Am Heart J 1999;138(3 pt 1):477-85.
(17.) Campeau L. Letter to the editor. Circulation 1976; 54:522.
(18.) Criteria Committee of the New York Heart Association. Diseases of the heart and blood vessels, nomenclature and criteria for diagnosis. 6th ed. Boston: Little, Brown, 1964.
This article is one in a series developed in collaboration with the American Heart Association. Guest editor of the series is Sidney C. Smith, Jr., M.D., Chief Science Officer, American Heart Association, Dallas.
MELVIN D. CHEITLIN, M.D., is emeritus professor of medicine at the University of California, San Francisco, School of Medicine. Dr. Cheitlin received his medical degree from Temple University School of Medicine, Philadelphia, and completed an internal medicine residency and a cardiovascular fellowship at Walter Reed Army Medical Center, Washington, D.C. Previously, Dr. Cheitlin was chief of the cardiology section at San Francisco General Hospital.
Address correspondence to Melvin D. Cheitlin, M.D., San Francisco General Hospital, Room 5G1, Cardiology Services, 1001 Potrero Ave., San Francisco, CA 94110 (e-mail: email@example.com). Reprints are not available from the author.
COPYRIGHT 2001 American Academy of Family Physicians
COPYRIGHT 2001 Gale Group